Ian Karp | executive |
John Leonard | executive |
David Lebwohl | executive |
Laura Sepp-Lorenzino | executive |
Glenn Goddard | executive |
Maurice Raycroft | analyst |
Reena Patel | analyst |
Joseph Thome | analyst |
Mehdi Goudarzi | analyst |
Harshita Polishetty | analyst |
Debjit Chattopadhyay | analyst |
Yanan Zhu | analyst |
Dae Gon Ha | analyst |
Myles Minter | analyst |
Sungin Yun | analyst |
William Pickering | analyst |
Rick Bienkowski | analyst |
Jay Olson | analyst |
Silvan Tuerkcan | analyst |
Nicholas Econom | analyst |
Jin Law | analyst |
Good morning, and welcome to the Intellia Therapeutics Second Quarter 2023 Earnings Conference Call. My name is Drew, and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. [Operator Instructions]